[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:hematologic-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":311,"states":340},"Hematologic Neoplasm",284,247,[8,16,22,28,34,41,48,55,61,67,73,79,85,91,97,103,109,115,121,127,133,139,145,151,157,163,169,175,181,187,192,198,204,211,217,223,229,235,241,247,253,259,265,271,277,282,288,294,299,305],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07220616","A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:15:15.642947Z","2026-07-05T05:32:16.664150Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07629726","A Phase 1\u002F2 Study of KK2430 in Participants With Hematologic Neoplasms",[12],"2026-08-26T02:19:05.360997Z","2026-06-06T00:48:49.532795Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05289167","Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)",[12],"2026-08-26T02:15:51.395565Z","2026-05-29T15:36:40.231796Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT05612789","Improve Outcomes for Older Allogeneic Transplant Recipients",[],"2026-08-26T02:17:49.709549Z","2026-05-05T02:47:14.263984Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":39,"content_modified":40},"NCT03486873","Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587\u002FKEYNOTE-587)",[38],"Phase 3","2026-08-26T02:19:24.527214Z","2026-05-05T02:43:29.706280Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT06828796","Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide",[45],"Phase 2","2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.703736Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":53,"content_modified":54},"NCT05443425","Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies",[52],"Phase 1","2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.411039Z",{"nct_id":56,"title":57,"phases":58,"status":13,"updated_at":59,"content_modified":60},"NCT07162038","Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation",[52],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.410020Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT06799195","Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation",[45],"2026-08-26T02:17:02.694423Z","2026-05-05T02:43:29.069245Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05849207","Post-Transplant Cyclophosphamide in Patients Aged >\u002F= 65 Years Undergoing Haploidentical Transplant",[52],"2026-08-26T02:16:06.684983Z","2026-05-05T02:43:28.966197Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT03850366","HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib",[45],"2026-08-26T02:19:12.219640Z","2026-05-05T02:43:28.291322Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT07006688","A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment",[52],"2026-08-26T02:18:58.141497Z","2026-05-05T02:43:28.011880Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT03089554","Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies",[45],"2026-08-26T02:15:33.331531Z","2026-05-05T02:43:27.838733Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07257419","CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+\u002FCD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed\u002FRefractory CD19+ ALL and Lymphoma",[52],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.676036Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT03838926","Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies",[52],"2026-08-26T02:18:17.950264Z","2026-05-05T02:43:27.489650Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT06784336","Phase II Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation",[45],"2026-08-26T02:17:39.857430Z","2026-05-05T02:43:27.475534Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07036133","Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment",[52],"2026-08-26T02:19:14.560989Z","2026-05-05T02:43:27.316252Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT04022239","Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant",[12],"2026-08-26T02:19:09.651016Z","2026-05-05T02:43:27.305663Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06470971","Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial",[45],"2026-08-26T02:16:39.977107Z","2026-05-05T02:43:27.263276Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07444268","How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers",[52],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:26.948851Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT04634552","A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma",[45],"2026-08-26T02:15:57.572488Z","2026-05-05T02:35:31.778397Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT05053867","A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients",[38],"2026-08-26T02:15:09.079045Z","2026-05-05T02:35:31.611420Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT07573111","Phase 1 Dose Escalation Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation",[52],"2026-08-26T02:17:23.750999Z","2026-05-13T02:55:06.778258Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT06704152","BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS",[12],"2026-08-26T02:18:18.766496Z","2026-05-05T02:43:29.733634Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT04167696","Study in Relapsed\u002FRefractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02",[52],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:29.586086Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT04953910","Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment",[52],"2026-08-26T02:16:07.529922Z","2026-05-05T02:43:29.584278Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT07493538","MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases",[45],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:28.880222Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT02074839","Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation",[52],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:27.599227Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06915116","Acupuncture for People Experiencing Period Loss Due to Chemotherapy",[45],"2026-08-26T02:15:58.452248Z","2026-05-05T02:43:27.590322Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":32,"content_modified":191},"NCT02203903","Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies",[52],"2026-05-05T02:43:27.423311Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT07155226","Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression",[12],"2026-08-26T02:15:17.167444Z","2026-05-05T02:43:27.256920Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT04953897","Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment",[52],"2026-08-26T02:18:38.077159Z","2026-05-05T02:43:27.092639Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":209,"content_modified":210},"NCT04512716","Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",[208],"Early Phase 1","2026-08-26T02:17:45.190188Z","2026-05-05T02:43:26.957051Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT06119685","IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers",[12],"2026-08-26T02:16:33.772093Z","2026-05-05T02:35:31.931545Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT06034275","Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies",[52],"2026-08-26T02:18:46.948970Z","2026-05-05T02:35:31.754345Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT05110742","Phase I\u002FII Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed\u002FRefractory Hematological Malignances",[12],"2026-08-26T02:18:40.612983Z","2026-07-30T01:46:14.462113Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT07572006","A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies",[52],"2026-08-26T02:18:31.164304Z","2026-07-24T01:27:14.897977Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT05877599","A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",[52],"2026-08-26T02:15:10.362237Z","2026-07-19T19:36:05.120541Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT06580002","Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial",[45],"2026-08-26T02:15:04.877798Z","2026-07-19T19:36:05.038415Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT04104776","A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas",[12],"2026-08-26T02:17:15.156099Z","2026-07-05T05:32:16.792523Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT06788964","Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)",[45],"2026-08-26T02:18:45.196599Z","2026-07-05T05:32:16.700465Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT04902443","Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV",[52],"2026-08-26T02:17:27.435233Z","2026-06-18T12:24:02.872345Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT07354100","Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy",[12],"2026-08-26T02:18:52.966503Z","2026-06-17T02:29:30.060269Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":275,"content_modified":276},"NCT07493304","Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers",[38],"2026-08-26T02:17:05.997056Z","2026-05-29T15:36:40.231786Z",{"nct_id":278,"title":279,"phases":280,"status":13,"updated_at":125,"content_modified":281},"NCT07451054","CD45BE-HSPC + CART-45 Cells",[52],"2026-05-13T02:55:06.706937Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":286,"content_modified":287},"NCT04318678","CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)",[52],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:29.730542Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT04640987","Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback",[52],"2026-08-26T02:19:00.742020Z","2026-05-05T02:43:29.667798Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":131,"content_modified":298},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[12],"2026-05-05T02:43:29.587324Z",{"nct_id":300,"title":301,"phases":302,"status":13,"updated_at":303,"content_modified":304},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[52],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.581486Z",{"nct_id":306,"title":307,"phases":308,"status":13,"updated_at":309,"content_modified":310},"NCT06708897","A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas",[52],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:29.367440Z",[312,316,320,324,327,330,334,337],{"biomarker":313,"count":314,"slug":315},"CD19 Gene",10,"cd19-gene",{"biomarker":317,"count":318,"slug":319},"HLA Complex",6,"hla-complex",{"biomarker":321,"count":322,"slug":323},"BCR\u002FABL1 Fusion Gene",5,"bcr-abl1-fusion-gene",{"biomarker":325,"count":322,"slug":326},"KMT2A Gene","kmt2a-gene",{"biomarker":328,"count":322,"slug":329},"MS4A1 Gene","ms4a1-gene",{"biomarker":331,"count":332,"slug":333},"HIV Infection",3,"hiv-infection",{"biomarker":335,"count":332,"slug":336},"IDH1 Gene","idh1-gene",{"biomarker":338,"count":332,"slug":339},"NPM1 Gene","npm1-gene",[341,345,349,353,357,361,365,368,371,375,378,382,386,390,394,397,401,405,409,413,416,420,424,428],{"state":342,"count":343,"slug":344},"Texas",69,"texas",{"state":346,"count":347,"slug":348},"California",54,"california",{"state":350,"count":351,"slug":352},"Florida",51,"florida",{"state":354,"count":355,"slug":356},"New York",50,"new-york",{"state":358,"count":359,"slug":360},"Minnesota",37,"minnesota",{"state":362,"count":363,"slug":364},"Maryland",35,"maryland",{"state":366,"count":363,"slug":367},"North Carolina","north-carolina",{"state":369,"count":363,"slug":370},"Ohio","ohio",{"state":372,"count":373,"slug":374},"Massachusetts",33,"massachusetts",{"state":376,"count":373,"slug":377},"Michigan","michigan",{"state":379,"count":380,"slug":381},"New Jersey",31,"new-jersey",{"state":383,"count":384,"slug":385},"Washington",29,"washington",{"state":387,"count":388,"slug":389},"Tennessee",28,"tennessee",{"state":391,"count":392,"slug":393},"Georgia",27,"georgia",{"state":395,"count":392,"slug":396},"Pennsylvania","pennsylvania",{"state":398,"count":399,"slug":400},"Arizona",24,"arizona",{"state":402,"count":403,"slug":404},"Oregon",21,"oregon",{"state":406,"count":407,"slug":408},"Illinois",20,"illinois",{"state":410,"count":411,"slug":412},"Missouri",19,"missouri",{"state":414,"count":411,"slug":415},"Wisconsin","wisconsin",{"state":417,"count":418,"slug":419},"Colorado",18,"colorado",{"state":421,"count":422,"slug":423},"Utah",14,"utah",{"state":425,"count":426,"slug":427},"Alabama",13,"alabama",{"state":429,"count":426,"slug":430},"District of Columbia","district-of-columbia"]